title: Abiraterone acetate: targeting persistent androgen dependence in castration-resistant prostate cancer.
abstract: Abiraterone acetate is the first second-line hormonal agent proven to improve survival in metastatic castration-resistant prostate cancer. It selectively inhibits cytochrome P450 17 (CYP17) α-hydroxylase and cytochrome17,20 (C17,20)-lyase, which are enzymes critical for androgen synthesis. Abiraterone acetate was initially approved in the United States in 2011 after demonstrating a 4-month survival benefit in docetaxel-refractory metastatic prostate cancer. The FDA recently expanded its indication for use in the pre-chemotherapy setting after it elicited significant delays in disease progression and a strong trend for increased overall survival in phase III studies. Ongoing investigations of abiraterone are evaluating its efficacy in earlier disease states, exploring its synergy in combination with other therapeutic agents, and assessing the necessity for administration of concurrent steroids and gonadal suppression. The identification and development of predictive biomarkers will optimize the incorporation of abiraterone into the management of advanced prostate cancer.
authors: Dana-Farber Cancer Institute, 450 Brookline Ave, DANA 1230, Boston, MA, 02215, USA, laurenc_harshman@dfci.harvard.edu.
authors: Lauren C
authors: LC
authors: Harshman
authors: Mary-Ellen
authors: ME
authors: Taplin
mesh_terms: D000069501:Abiraterone Acetate; D000730:Androstadienes / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D018572:Disease-Free Survival; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis / Q000188:drug therapy*; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000473:pathology; D013254:Steroid 17-alpha-Hydroxylase / Q000037:antagonists & inhibitors*; D016896:Treatment Outcome
chemical_list: D000730:Androstadienes; D018931:Antineoplastic Agents, Hormonal; D013254:Steroid 17-alpha-Hydroxylase; D000069501:Abiraterone Acetate
references: J Med Chem. 1995 Jun 23;38(13):2463-71
references: 7608911
references: J Clin Oncol. 2010 Mar 20;28(9):1496-501
references: 20159814
references: J Clin Oncol. 2009 Aug 10;27(23):3742-8
references: 19470933
references: J Urol. 2001 Aug;166(2):500-6; discussion 506-7
references: 11458055
references: BMC Cancer. 2010 Oct 14;10:556
references: 20946682
references: Br J Cancer. 2004 Jun 14;90(12):2317-25
references: 15150570
references: J Clin Oncol. 2008 Oct 1;26(28):4563-71
references: 18645193
references: Cancer Res. 1999 Sep 1;59(17):4291-6
references: 10485474
references: N Engl J Med. 2013 Jan 10;368(2):138-48
references: 23228172
references: J Urol. 1998 Jan;159(1):149-53
references: 9400459
references: Cancer Lett. 1999 Jul 1;141(1-2):173-8
references: 10454259
references: Cancer Res. 2006 Mar 1;66(5):2815-25
references: 16510604
references: N Engl J Med. 1995 May 25;332(21):1393-8
references: 7723794
references: Mol Endocrinol. 1991 Dec;5(12):1921-30
references: 1724287
references: J Clin Oncol. 2002 Jul 1;20(13):3001-15
references: 12089231
references: Front Biosci. 2007 Sep 01;12:4957-71
references: 17569623
references: Clin Cancer Res. 2007 Mar 1;13(5):1493-502
references: 17332294
references: BJU Int. 2005 Dec;96(9):1241-6
references: 16287438
references: Clin Cancer Res. 1997 Aug;3(8):1383-8
references: 9815822
references: Lancet. 2011 Mar 5;377(9768):813-22
references: 21353695
references: BJU Int. 2005 Oct;96(6):783-6
references: 16153200
references: Cancer Res. 2009 Jan 1;69(1):16-22
references: 19117982
references: Clin Cancer Res. 2009 Nov 15;15(22):7099-105
references: 19887483
references: Proc Natl Acad Sci U S A. 2011 Aug 16;108(33):13728-33
references: 21795608
references: J Clin Oncol. 1999 Aug;17(8):2506-13
references: 10561316
references: Lancet. 2012 Jan 7;379(9810):39-46
references: 22093187
references: J Steroid Biochem Mol Biol. 2000 Dec 1;75(1):1-10
references: 11179903
references: BJU Int. 2005 Oct;96(6):787-90
references: 16153201
references: Urology. 2002 Dec;60(6):1113-7
references: 12475693
references: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references: 22237781
references: Cancer Res. 2007 May 15;67(10):5033-41
references: 17510436
references: N Engl J Med. 1989 Aug 17;321(7):419-24
references: 2503724
references: N Engl J Med. 2012 Sep 27;367(13):1256-7
references: 23013078
references: J Clin Endocrinol Metab. 2006 Oct;91(10):3850-6
references: 16882745
references: Cancer Res. 2009 Mar 15;69(6):2305-13
references: 19244107
references: Adv Cancer Res. 2004;91:31-67
references: 15327888
references: World J Urol. 2008 Jun;26(3):205-10
references: 18401585
references: Cancer Res. 2007 Feb 1;67(3):967-75
references: 17283128
references: Urology. 2002 Sep;60(3 Suppl 1):132-8; discussion 138-9
references: 12231070
references: N Engl J Med. 2011 May 26;364(21):1995-2005
references: 21612468
references: Clin Cancer Res. 2011 Jul 15;17(14):4854-61
references: 21632851
references: J Clin Oncol. 2003 Jul 15;21(14):2673-8
references: 12860943
references: J Clin Oncol. 2012 Feb 20;30(6):637-43
references: 22184395
references: Lancet. 2010 Oct 2;376(9747):1147-54
references: 20888992
references: Clin Cancer Res. 2011 Jun 15;17(12):3876-83
references: 21680543
references: Ann Oncol. 2013 Apr;24(4):1017-25
references: 23152362
references: Urology. 2000 Aug 1;56(2):289-94
references: 10925096
references: N Engl J Med. 2004 Oct 7;351(15):1502-12
references: 15470213
references: J Clin Oncol. 2010 Mar 20;28(9):1489-95
references: 20159823
references: J Clin Oncol. 2012 Feb 20;30(6):644-6
references: 22184375
references: J Clin Oncol. 2010 Mar 20;28(9):1481-8
references: 20159824
references: J Clin Oncol. 2008 Mar 1;26(7):1148-59
references: 18309951
references: Mol Endocrinol. 1997 Feb;11(2):148-61
references: 9013762
references: Lancet Oncol. 2012 Oct;13(10):983-92
references: 22995653
references: Cancer Res. 1997 Nov 15;57(22):4997-5000
references: 9371490
references: J Clin Oncol. 1996 Jun;14(6):1756-64
references: 8656243
references: J Clin Invest. 2010 Aug;120(8):2715-30
references: 20644256
references: Clin Cancer Res. 2011 Apr 1;17(7):1649-57
references: 21372223
references: N Engl J Med. 2012 Sep 27;367(13):1187-97
references: 22894553
references: Lancet Oncol. 2012 Dec;13(12):1210-7
references: 23142059
references: N Engl J Med. 2010 Jul 29;363(5):411-22
references: 20818862
references: Urology. 2001 Dec;58(6):1016-20
references: 11744479
references: Science. 2009 May 8;324(5928):787-90
references: 19359544
references: J Clin Oncol. 2004 Mar 15;22(6):1025-33
references: 15020604
references: Cancer. 2002 Jul 15;95(2):361-76
references: 12124837